Cara Therapeutics Reports Second Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Cara Therapeutics (CARA) Tops Q2 EPS by 18c
August 8, 2022 4:30 PM EDTCara Therapeutics (NASDAQ: CARA) reported Q2 EPS of ($0.08), $0.18 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $23 million versus the consensus estimate of $21.11 million.
For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.
... More